Higher margins and new drugs help GlaxoSmithKline beat forecasts

Signage for GlaxoSmithKline is seen on it's offices in London, BritainBy Ben Hirschler LONDON (Reuters) – Improving margins in consumer health and growing demand for new drugs lifted GlaxoSmithKline's underlying earnings a better-than-expected 14 percent in the first quarter, keeping it on course to achieve a promised return to growth in 2016. The results may help vindicate the claims of outgoing Chief Executive Andrew Witty that the British drugmaker is on the road to recovery, with demand for new respiratory and HIV medicines offsetting a decline in sales of aging lung treatment Advair.



Sexual Health News Headlines – Yahoo! News

Higher margins and new drugs help GlaxoSmithKline beat forecasts

Signage for GlaxoSmithKline is seen on it's offices in London, BritainBy Ben Hirschler LONDON (Reuters) – Improving margins in consumer health and growing demand for new drugs lifted GlaxoSmithKline's underlying earnings a better-than-expected 14 percent in the first quarter, keeping it on course to achieve a promised return to growth in 2016. The results may help vindicate the claims of outgoing Chief Executive Andrew Witty that the British drugmaker is on the road to recovery, with demand for new respiratory and HIV medicines offsetting a decline in sales of aging lung treatment Advair.



Sexual Health News Headlines – Yahoo! News